Preventing Respiratory Syncytial Virus in Children in France : A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities
© 2022. The Author(s)..
The highly contagious respiratory syncytial virus (RSV) is responsible for up to approximately 50,000 hospitalisations during each RSV season in children aged under 5 years in France, with the burden greatest in infants younger than 1 year who were born at term. There is a need for a strategy to universally protect young children from RSV infection, and thereby reduce the pressure that RSV places every year on RSV-infected children, their parents, and French healthcare systems. Potential strategies currently undergoing clinical investigation include passive immunisation via maternal vaccination or administration of long-acting monoclonal antibodies at or soon after birth, followed by vaccination later in infancy or childhood. An ongoing partnership and collaboration between parents, public health authorities, and frontline primary healthcare will need to be reinforced once these new RSV prevention strategies are available, to facilitate their use and ensure that all children receive adequate protection from the start of their first RSV season.
| Errataetall: |
ErratumIn: Infect Dis Ther. 2023 Jun;12(6):1739-1740. - PMID 37179278 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 12(2023), 2 vom: 15. Feb., Seite 317-332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pinquier, Didier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Children |
|---|
| Anmerkungen: |
Date Revised 16.05.2023 published: Print-Electronic ErratumIn: Infect Dis Ther. 2023 Jun;12(6):1739-1740. - PMID 37179278 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-022-00737-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350322619 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350322619 | ||
| 003 | DE-627 | ||
| 005 | 20231226044734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-022-00737-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350322619 | ||
| 035 | |a (NLM)36520324 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pinquier, Didier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preventing Respiratory Syncytial Virus in Children in France |b A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Infect Dis Ther. 2023 Jun;12(6):1739-1740. - PMID 37179278 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a The highly contagious respiratory syncytial virus (RSV) is responsible for up to approximately 50,000 hospitalisations during each RSV season in children aged under 5 years in France, with the burden greatest in infants younger than 1 year who were born at term. There is a need for a strategy to universally protect young children from RSV infection, and thereby reduce the pressure that RSV places every year on RSV-infected children, their parents, and French healthcare systems. Potential strategies currently undergoing clinical investigation include passive immunisation via maternal vaccination or administration of long-acting monoclonal antibodies at or soon after birth, followed by vaccination later in infancy or childhood. An ongoing partnership and collaboration between parents, public health authorities, and frontline primary healthcare will need to be reinforced once these new RSV prevention strategies are available, to facilitate their use and ensure that all children receive adequate protection from the start of their first RSV season | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a France | |
| 650 | 4 | |a Immunisation | |
| 650 | 4 | |a Infants | |
| 650 | 4 | |a Nirsevimab | |
| 650 | 4 | |a Palivizumab | |
| 650 | 4 | |a Pharmacoeconomics | |
| 650 | 4 | |a Primary healthcare | |
| 650 | 4 | |a Public health | |
| 650 | 4 | |a Respiratory syncytial virus | |
| 700 | 1 | |a Crépey, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Tissières, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Vabret, Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Roze, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Dubos, François |e verfasserin |4 aut | |
| 700 | 1 | |a Cahn-Sellem, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Javouhey, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Weil-Olivier, Catherine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 12(2023), 2 vom: 15. Feb., Seite 317-332 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:2 |g day:15 |g month:02 |g pages:317-332 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-022-00737-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 2 |b 15 |c 02 |h 317-332 | ||